receive daily
reports of the
TOP PICKS
OR
your personal
stock choices
| Click Here to receive daily reports of the TOP PICKS OR your personal stock choices | STOCKCHASEWhat the experts are saying! |
|
| There are 2 registered members and 90 guests viewing the site. | Follow us on Twitter |  Rss Top Picks Feed | Rss Daily Feed |
|
| HOLD | 1.830 | Hap (Robert) Sneddon FCSI | Broke through the 200-day moving average at about $1.50. Looks like the momentum may start to peter out but there is some pretty good support around $1.40. If her broke that, you should Sell. | 2009-01-08 | |
| DON'T BUY | 1.070 | Peter Hodson | Has disappointed everyone for a long time. Didn't get approval on their product. Stock has been decimated. Thinks the worst is over, but it will be a long recovery. He was actually Short the stock for a while. If you own, Hold and see what they do, but don't be a buyer. | 2007-12-14 | |
| SELL | 1.230 | Lesley Marks | Has been a major disappointment. Guided that approvals would be fairly easy to receive, which didn't happen. Trials have been okay, not all that inclusive, so there is a lot of uncertainty. | 2007-11-15 | |
| BUY | 5.560 | Chyanne Fickes | Has been doing fairly well recently because they had their European and Canadian approval for their painkiller. Once they get the US of the way, it should be back over the $7 mark. | 2006-11-06 | |
| BUY | 5.830 | Chyanne Fickes | It is a small stock. Believes it will be a winner. | 2006-10-02 | |
| WATCH | 4.890 | Peter Hodson | Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in. | 2005-08-23 | |
| DON'T BUY | 4.170 | Andrew McCreath | Received approval in France for its drug tramadol. Has stubbed its toes many times with investors. Large outstanding stock holding (40 Million?) could come out and flood the market. | 2005-01-17 | |
| DON'T BUY | 4.170 | David Baskin | Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter. | 2005-01-17 | |
| WATCH | 4.030 | Glenn Paradis, BA, CFA | Management is at its risk. If they start in Europe, the stock will improve. Therefore, be cautious. | 2004-08-26 | |
| DON'T BUY | 4.090 | Peter Hodson | Did an issue and it was a disaster. Hasn't even come close to where the issue was priced at. Behind schedule as compared to their competitors. | 2004-05-17 | |
| DON'T BUY | 5.180 | Andrew McCreath | Still suffering from a plethora of disappointments from late 2001 and 2002. Will have a challenge moving up from where it is. Prefers others. | 2003-05-29 | |
| DON'T BUY | 5.340 | Bruce Cooper | Volatile. Too few projects on the go. Risky. | 2002-05-17 | |
| DON'T BUY | 4.750 | Bruce Cooper | Interesting technology. Future is unclear. Risky. | 2002-05-02 | |
| PAST TOP PICK | 5.800 | Glenn Paradis, BA, CFA | (Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal. | 2002-04-01 | |
| DON'T BUY | 5.380 | Jonathen Wellum, B. Comm, B. Sc | Speculative and risky. In a competitive sector. | 2002-03-15 | |
| DON'T BUY | 5.000 | Robert Floyd | Would have some questions before buying this stock. | 2002-03-14 | |
| BUY | 9.650 | Brendan Kyne | Good product. Has risen very fast and will probably pause for a while. Good price for long term. | 2002-02-18 | |
| PAST TOP PICK | 10.450 | Brendan Kyne | (Was a top pick on Oct 26 up 50%) Still likes. | 2002-01-24 | |
| BUY | 10.150 | Glenn Paradis, BA, CFA | Agreat future. Lots of risks involved, but the reward should be good. Just completed 2 big deals. | 2002-01-17 | |
|
| |||||
| BUY on WEAKNESS | 10.850 | Brian Acker, CA | No earnings. Buy on a pull back. Speculation. | 2001-12-28 | |
| BUY | 11.500 | Michael Smedley | Moving up well and should continue. | 2001-12-24 | |
| TOP PICK | 10.100 | Glenn Paradis, BA, CFA | Making good contracts. | 2001-12-18 | |
| BUY on WEAKNESS | 9.490 | Bruce Cooper | Good partnership. A lot of potential. Pretty high right now. | 2001-11-29 | |
| TOP PICK | 7.940 | Brendan Kyne | Good product. New agreement is good. | 2001-11-12 | |
| TOP PICK | 7.050 | Brendan Kyne | Raised $40 million in financing. Good agreements. | 2001-10-26 | |
| TOP PICK | 6.450 | Brendan Kyne | Has good potential. Low market cap of $160 million. Good mngmnt. Good alliance. Lots of cash. | 2001-10-01 | |
| TOP PICK | 6.150 | Brendan Kyne | Good alliances. | 2001-09-04 | |
| TOP PICK | 6.120 | Brendan Kyne | Lots of cash. Good mngmnt. | 2001-07-04 |
